Statistics

Total Visits

Views
Long-term progression-free-survival (PFS) under sunitinib (SU) treatment for metastatic renal cell carcinoma (Sulong study): Analysis of two populations - long term responders (LR) vs. primary refractory (PR) patients6

Select a period of time:

Number of views in the range

Views
Long-term progression-free-survival (PFS) under sunitinib (SU) treatment for metastatic renal cell carcinoma (Sulong study): Analysis of two populations - long term responders (LR) vs. primary refractory (PR) patients3

Views

Views
November 20230
December 20230
January 20241
February 20240
March 20240
April 20240
May 20242
Download CSV file
 untranslated
 untranslated

Top country views

Views
United States3
 

Top cities views

Views
Boardman1